Scandion Oncology (Scandion) announced the poster presentation of clinical safety and PK data from its PANTAX trial at the European Society for Medical Oncology (ESMO) Congress 2023 starting on October 20th in Madrid. The poster presents data analysis from the PANTAX phase Ib trial, studying Scandion's lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. Topline results were announced in March 2023.

The data confirms that SCO-101 is safe and well-tolerated in this indication and combination, thereby also supporting the general profile of SCO-101 as well-tolerated in combination with different chemotherapies in patients with late-stage disease. In the trial, dose limiting toxicity were observed in two patients in the cohort treated with 250 milligram of SCO-101, hence the maximum tolerated dose for SCO-101 concurrent with gemcitabine and sn-paclitaxel was determined to be 200 milligram once daily for 6 days on a bi-weekly schedule. Data from the PK profile demonstrated that a 6-day schedule of SCO-101 resulted in SCO-101 accumulation and drug-exposure proportional to dose.

Scandion expects to present a final analysis of all safety and efficacy outcomes from PANTAX in the first half of 2024.